UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Emplo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to ________ Commission file number: 001-35593 HOMETRUST BANCSHARES, INC. (Exact name of registrant as specified in its charter) Maryland 45-5055422 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission file number 001-39510 STEPSTONE GROUP INC. (Exact name of Registrant as specified in its charter) D ...

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 Exhibit 99.1 vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousan ...

EXHIBIT 99.1 og resources November 6, 2025 EOG Resources Reports Third Quarter 2025 Results HOUSTON - (PR Newswire) - EOG Resources, Inc. (EOG) today reported third quarter 2025 results. The attached supplemental financial tables and schedules for the reconciliation of non-GAAP measures to GAAP measures and related definitions and discussion, along with a related presentation, are also available on EOG's website at http://investors.eogresources.com/investors. Key Financial Results In millions of USD, except ...

| | | September 30, | | December 31, | | --- | --- | --- | --- | --- | | | | 2025 | | 2024 | | ASSETS | | (Unaudited) | | | | Current assets: | | | | | | Cash and cash equivalents | $ | 268,936 | $ | 198,240 | | Accounts receivable, net of allowances of $3,466 and $726 as of September 30, 2025 and December 31, 2024, respectively | | 22,417 | | 23,159 | | Contract assets and unbilled receivable, net | | 32,178 | | 26,645 | | Other current assets | | 11,835 | | 7,476 | | Total current assets | | 335,366 | | 2 ...

SUPPLEMENTAL FINANCIAL INFORMATION FOR THREE MONTHS ENDED SEPTEMBER 30, 2025 November 6, 2025 60 Cutter Mill Rd., Great Neck, NY 11021 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Exhibit 99.1 We consider some of the information set forth herein to contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, with respect to our expect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION American Coastal Insurance Corporation (Exact Name of Registrant as Specified in its Charter) WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35761 (State or Other J ...

Financial Performance - Lifecore Biomedical recorded $31.1 million in revenue for the three months ended September 30, 2025, representing a 26% increase from $24.7 million in the comparable prior period[11] - The company achieved a gross profit of $7.8 million, up from $5.4 million in the prior year, driven by a $4.3 million increase in HA manufacturing gross profit[13] - Total revenues for the three months ended September 30, 2025, were $31,109,000, a 25.9% increase from $24,705,000 for the same period in 2024[35] - Gross profit for the same period was $7,791,000, compared to $5,387,000 in the prior year, reflecting a 44.6% increase[35] - Adjusted EBITDA for the three months ended September 30, 2025, was $3,050,000, a significant improvement from a loss of $1,793,000 in the same period of 2024[38] - Lifecore's Adjusted EBITDA for the period was $3.1 million, an increase of $4.9 million compared to a negative $1.8 million in the prior year[16] - The net loss for the three months ended September 30, 2025, was $9,991,000, an improvement from a net loss of $16,230,000 in the same period of 2024[35] - Estimated net loss for the seven-month transition period from May 26, 2025, to December 31, 2025, is projected to be between $18,400,000 and $16,400,000[40] Cost Management - Selling, general and administrative expenses decreased by $5.9 million to $8.9 million compared to $14.8 million in the prior period, reflecting cost management efforts[14] - The company plans to launch a new ERP system in Q1 2026 to enhance inventory control and financial management, contributing to cost reduction[12] Operational Efficiency - Lifecore has improved workforce productivity in manufacturing by over 20% over the past year, reflecting its commitment to operational efficiency[12] - The company is focused on maximizing existing customer business and advancing late-stage development programs towards commercialization[3] Future Outlook - The company expects revenue for the transition period from May 26 to December 31, 2025, to be approximately $74 to $76 million, with a net loss projected between $18.4 million and $16.4 million[19] - Lifecore aims for a revenue CAGR of 12%+ and adjusted EBITDA margins exceeding 25% over the mid-term[3] - The company aims to achieve a revenue CAGR of over 12% and increase Adjusted EBITDA margins to more than 25% in the mid-term[30] Balance Sheet - The current assets as of September 30, 2025, totaled $83,928,000, slightly down from $85,677,000 as of May 25, 2025[33] - The total liabilities as of September 30, 2025, were $198,418,000, compared to $191,909,000 as of May 25, 2025[33] - The company reported a weighted average of 37,402,912 shares outstanding for the three months ended September 30, 2025[35] Corporate Changes - The company plans to transition its fiscal year end to align with the calendar year, effective for the December 31, 2025, period[39] - Lifecore signed two new programs during the quarter, including one late-stage and one early-stage program, expanding its service capabilities beyond ophthalmic therapeutics[6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35761 American Coastal Insurance Corporation (Exact Name of Registrant as Specified in its Charter) (State or Other J ...